Tango Therapeutics Receives Favorable Coverage from Piper Sandler, Set to Capitalize on Precision Oncology Field
Monday saw Piper Sandler initiate coverage on Tango Therapeutics Inc. (NASDAQ:TNGX), giving the company an Overweight rating and setting a price target of $18.00. The investment firm’s analysis showcases Tango’s MTA-cooperative PRMT5 inhibitor portfolio, highlighting its strong position in the precision oncology field.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
